孕期RSVpreF接种与妊娠期高血压疾病风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入9项研究(3项RCT、6项回顾性队列,n=148,267),评估孕期RSVpreF接种与妊娠期高血压疾病(HDP)风险的关联。I2=44%),主要归因于妊娠期高血压,子痫前期/子痫无显著关联。
要点
- 该关联主要归因于妊娠期高血压,子痫前期/子痫无显著关联。
- 关联主要由观察性研究驱动,RCT显示方向一致但无统计学显著性。
核心结论
- 孕期RSVpreF接种与HDP风险小幅升高相关,主要归因于妊娠期高血压,且主要由观察性研究驱动,残余混杂可能仍存在。
- 婴儿RSV预防的获益仍然显著,这些发现支持继续开展上市后监测和知情共同决策。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase、CENTRAL、Scopus、ClinicalTrials.gov和WHO ICTRP从建库至2026年1月26日。
- 纳入比较RSVpreF接种与未接种或安慰剂受试孕妇HDP结局的RCT和观察性研究,共9项研究(3项RCT、6项回顾性队列研究;n=148,267)。
- 未调整风险比(RR)采用随机效应模型合并;观察性研究的调整估计值采用逆方差法单独合并。
- 研究注册于PROSPERO(CRD420251026835)。
主要发现
- 关联归因于妊娠期高血压,子痫前期/子痫无显著关联。
临床怎么用
- 孕期RSVpreF接种决策应权衡婴儿RSV预防获益与HDP风险小幅升高,开展知情共同决策。
- 继续开展上市后监测以进一步评估RSVpreF接种与HDP的关联。
局限性
- 关联主要由观察性研究驱动,残余混杂可能仍存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVpreF) was approved in the United States in August 2023 for use during pregnancy to prevent infant RSV-associated lower respiratory tract disease. The pivotal phase 3 trial identified a numerical imbalance in hypertensive disorders of pregnancy (HDP) that did not reach statistical significance; postmarketing observational studies have since reported inconsistent findings. We conducted a systematic review and meta-analysis to assess this association. METHODS: We searched MEDLINE, Embase, CENTRAL, Scopus, ClinicalTrials.gov, and WHO ICTRP from inception to Jan 26, 2026, for randomized controlled trials (RCTs) and observational studies comparing HDP outcomes in RSVpreF-vaccinated versus unvaccinated or placebo-receiving pregnant individuals. Unadjusted risk ratios (RRs) were pooled using a random-effects model; adjusted estimates from observational studies were pooled separately by inverse variance methods. This study is registered with PROSPERO (CRD420251026835). RESULTS: Nine studies were included (3 RCTs, 6 retrospective cohort studies; n = 148,267). RSVpreF vaccination was associated with a small but statistically significant increase in overall HDP risk (RR 1·08, 95% CI 1·02-1·13; p = 0·004; I2 = 44%), driven by the observational studies group (1·08, 1·02-1·14; I2 = 61%); RCTs showed a directionally consistent but non-significant RR (1·12, 0·87-1·43; I2 = 0%). The association was attributable to gestational hypertension, with no significant association for preeclampsia/eclampsia. CONCLUSION: Maternal RSVpreF vaccination was associated with a small increase in HDP attributable to gestational hypertension and driven primarily by observational studies, in which residual confounding remains possible. The benefits of infant RSV prevention remain substantial, and these findings support continued postmarketing surveillance and informed shared decision-making.
引用
- Alami A, Lewis M, El-Chaâr D, et al. Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis. Vaccine. 2026. PMID: 42667900. doi:10.1016/j.vaccine.2026.129070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。